Notice of Proposed Sale · 144
Adaptive Biotechnologies Corporation
ADPTNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Adaptive Biotechnologies Corporation
- Issuer CIK
- 0001478320
- SEC file number
- 001-38957
- Phone
- 1-206-659-0067
- Person for whose account securities are to be sold
- Harlan Robins
- Relationships to issuer
- Former Officer
- Street
- 1165 Eastlake Avenue East
- City
- Seattle
- State / country code
- WA
- Postal code
- 98109
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 402,160 | 10,230,950.4 | 159,595,842 | 08/20/2026 | NASD | Goldman Sachs & Co. LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Goldman Sachs & Co. LLC
- Street
- 200 West Street
- City
- New York
- State / country code
- NY
- Postal code
- 10282
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 03/04/2022 | Acquired as compensation -- Stock Options | The Issuer | 402,160 | N | 03/04/2022 | Compensation -- Cashless exercise / same-day sale |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Harlan Robins | Common Stock | 06/15/2026 | 100,000 | 1,737,460 |
| Harlan Robins | Common Stock | 06/16/2026 | 6,160 | 110,945.91 |
| Harlan Robins | Common Stock | 07/02/2026 | 136,240 | 2,936,094.62 |
| Harlan Robins | Common Stock | 07/02/2026 | 250,000 | 5,565,550 |
| Harlan Robins | Common Stock | 07/21/2026 | 207,600 | 4,538,136 |
| Harlan Robins | Common Stock | 07/21/2026 | 284,800 | 6,225,728 |
| Harlan Robins | Common Stock | 08/17/2026 | 152,036 | 3,765,931.72 |
| Harlan Robins | Common Stock | 08/17/2026 | 148,956 | 3,689,640.12 |
| Harlan Robins | Common Stock | 08/18/2026 | 261,044 | 6,411,240.64 |
| Harlan Robins | Common Stock | 08/19/2026 | 215,632 | 5,496,459.68 |
Seller — prior-sale row 1, entry 1
- Name
- Harlan Robins
- Street
- 1165 Eastlake Avenue East
- City
- Seattle
- State / country code
- WA
- Postal code
- 98109
Seller — prior-sale row 2, entry 1
- Name
- Harlan Robins
- Street
- 1165 Eastlake Avenue East
- City
- Seattle
- State / country code
- WA
- Postal code
- 98109
Seller — prior-sale row 3, entry 1
- Name
- Harlan Robins
- Street
- 1165 Eastlake Avenue East
- City
- Seattle
- State / country code
- WA
- Postal code
- 98109
Seller — prior-sale row 4, entry 1
- Name
- Harlan Robins
- Street
- 1165 Eastlake Avenue East
- City
- Seattle
- State / country code
- WA
- Postal code
- 98109
Seller — prior-sale row 5, entry 1
- Name
- Harlan Robins
- Street
- 1165 Eastlake Avenue East
- City
- Seattle
- State / country code
- WA
- Postal code
- 98109
Seller — prior-sale row 6, entry 1
- Name
- Harlan Robins
- Street
- 1165 Eastlake Avenue East
- City
- Seattle
- State / country code
- WA
- Postal code
- 98109
Seller — prior-sale row 7, entry 1
- Name
- Harlan Robins
- Street
- 1165 Eastlake Avenue East
- City
- Seattle
- State / country code
- WA
- Postal code
- 98109
Seller — prior-sale row 8, entry 1
- Name
- Harlan Robins
- Street
- 1165 Eastlake Avenue East
- City
- Seattle
- State / country code
- WA
- Postal code
- 98109
Seller — prior-sale row 9, entry 1
- Name
- Harlan Robins
- Street
- 1165 Eastlake Avenue East
- City
- Seattle
- State / country code
- WA
- Postal code
- 98109
Seller — prior-sale row 10, entry 1
- Name
- Harlan Robins
- Street
- 1165 Eastlake Avenue East
- City
- Seattle
- State / country code
- WA
- Postal code
- 98109
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 08/20/2026
- Signed
- Goldman Sachs & Co. LLC on behalf of Harlan Robins
Company context
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.